Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost | Zendy

Katz | Zendy; Clark Springs | Zendy; E. Randy Craven | Zendy; Montecchi-Palmer | Zendy

Open Access

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

Author(s) -

Katz,

Clark Springs,

E. Randy Craven,

Montecchi-Palmer

Publication year - 2010

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s14113

Subject(s) - travoprost , latanoprost , medicine , glaucoma , ophthalmology , intraocular pressure , ocular hypertension , prostaglandin analogue , benzalkonium chloride , open angle glaucoma , pathology

The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switched to a BAK-free therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research